Myeloid Sarcoma

Mohamed Magdy, Nagla Fawzy Miligy Abdel Karim, Ihab Eldessouki, Ola Gaber, Mohamed Rahouma, Mohamed Ghareeb

Research output: Contribution to journalReview article

Abstract

Hematological malignancies can manifest as extramedullary soft tissue masses in relatively rare cases. The rarity of it causes a diagnostic and therapeutic challenge. One of the rarest manifestations is myeloid sarcoma (MS). MS develops as part of acute myeloid leukemia, myeloproliferative neoplasm, or myelodysplastic syndrome or at relapse, especially following allogeneic hematopoietic stem cell transplant. The tumor displays high myeloperoxidase expression, hence the color green, and is called chloroma. It most commonly appears in lymph nodes, skin and soft tissues, bone, testes, gastrointestinal tract, and peritoneum. Immunohistochemistry shows CD68-KP1 as the most commonly expressed marker, then myeloperoxidase, CD117, CD99, CD68/PG-M1, lysozyme, CD34, terminal deoxynucleotidyl transferase, CD56, CD61, CD30, glycophorin A, and CD4. Different chromosomal abnormalities including MLL rearrangement, t(8; 21), monosomy 7, trisomy 8, trisomy 11, trisomy 4, inversion (16), monosomy 16,16q deletion, 5q deletion, and 20q deletion were reported. Most of the literature about MS are case reports and small retrospective studies, thus there is limited clinical knowledge of the cases and their presentation and management plans. Here, we provide a review of what has been reported in the literature about MS in the light of our experiences.

Original languageEnglish (US)
Pages (from-to)219-224
Number of pages6
JournalOncology Research and Treatment
Volume42
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Myeloid Sarcoma
Trisomy
Peroxidase
Glycophorin
Monosomy
DNA Nucleotidylexotransferase
Peritoneum
Myelodysplastic Syndromes
Hematologic Neoplasms
Muramidase
Hematopoietic Stem Cells
Acute Myeloid Leukemia
Chromosome Aberrations
Gastrointestinal Tract
Testis
Neoplasms
Retrospective Studies
Color
Lymph Nodes
Immunohistochemistry

Keywords

  • Chloroma
  • Extramedullary soft tissue masses
  • Myeloid sarcoma
  • Sarcoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Magdy, M., Abdel Karim, N. F. M., Eldessouki, I., Gaber, O., Rahouma, M., & Ghareeb, M. (2019). Myeloid Sarcoma. Oncology Research and Treatment, 42(4), 219-224. https://doi.org/10.1159/000497210

Myeloid Sarcoma. / Magdy, Mohamed; Abdel Karim, Nagla Fawzy Miligy; Eldessouki, Ihab; Gaber, Ola; Rahouma, Mohamed; Ghareeb, Mohamed.

In: Oncology Research and Treatment, Vol. 42, No. 4, 01.04.2019, p. 219-224.

Research output: Contribution to journalReview article

Magdy, M, Abdel Karim, NFM, Eldessouki, I, Gaber, O, Rahouma, M & Ghareeb, M 2019, 'Myeloid Sarcoma', Oncology Research and Treatment, vol. 42, no. 4, pp. 219-224. https://doi.org/10.1159/000497210
Magdy M, Abdel Karim NFM, Eldessouki I, Gaber O, Rahouma M, Ghareeb M. Myeloid Sarcoma. Oncology Research and Treatment. 2019 Apr 1;42(4):219-224. https://doi.org/10.1159/000497210
Magdy, Mohamed ; Abdel Karim, Nagla Fawzy Miligy ; Eldessouki, Ihab ; Gaber, Ola ; Rahouma, Mohamed ; Ghareeb, Mohamed. / Myeloid Sarcoma. In: Oncology Research and Treatment. 2019 ; Vol. 42, No. 4. pp. 219-224.
@article{25a4740cea04476489f930a4f03c1347,
title = "Myeloid Sarcoma",
abstract = "Hematological malignancies can manifest as extramedullary soft tissue masses in relatively rare cases. The rarity of it causes a diagnostic and therapeutic challenge. One of the rarest manifestations is myeloid sarcoma (MS). MS develops as part of acute myeloid leukemia, myeloproliferative neoplasm, or myelodysplastic syndrome or at relapse, especially following allogeneic hematopoietic stem cell transplant. The tumor displays high myeloperoxidase expression, hence the color green, and is called chloroma. It most commonly appears in lymph nodes, skin and soft tissues, bone, testes, gastrointestinal tract, and peritoneum. Immunohistochemistry shows CD68-KP1 as the most commonly expressed marker, then myeloperoxidase, CD117, CD99, CD68/PG-M1, lysozyme, CD34, terminal deoxynucleotidyl transferase, CD56, CD61, CD30, glycophorin A, and CD4. Different chromosomal abnormalities including MLL rearrangement, t(8; 21), monosomy 7, trisomy 8, trisomy 11, trisomy 4, inversion (16), monosomy 16,16q deletion, 5q deletion, and 20q deletion were reported. Most of the literature about MS are case reports and small retrospective studies, thus there is limited clinical knowledge of the cases and their presentation and management plans. Here, we provide a review of what has been reported in the literature about MS in the light of our experiences.",
keywords = "Chloroma, Extramedullary soft tissue masses, Myeloid sarcoma, Sarcoma",
author = "Mohamed Magdy and {Abdel Karim}, {Nagla Fawzy Miligy} and Ihab Eldessouki and Ola Gaber and Mohamed Rahouma and Mohamed Ghareeb",
year = "2019",
month = "4",
day = "1",
doi = "10.1159/000497210",
language = "English (US)",
volume = "42",
pages = "219--224",
journal = "Oncology Research and Treatment",
issn = "2296-5270",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Myeloid Sarcoma

AU - Magdy, Mohamed

AU - Abdel Karim, Nagla Fawzy Miligy

AU - Eldessouki, Ihab

AU - Gaber, Ola

AU - Rahouma, Mohamed

AU - Ghareeb, Mohamed

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Hematological malignancies can manifest as extramedullary soft tissue masses in relatively rare cases. The rarity of it causes a diagnostic and therapeutic challenge. One of the rarest manifestations is myeloid sarcoma (MS). MS develops as part of acute myeloid leukemia, myeloproliferative neoplasm, or myelodysplastic syndrome or at relapse, especially following allogeneic hematopoietic stem cell transplant. The tumor displays high myeloperoxidase expression, hence the color green, and is called chloroma. It most commonly appears in lymph nodes, skin and soft tissues, bone, testes, gastrointestinal tract, and peritoneum. Immunohistochemistry shows CD68-KP1 as the most commonly expressed marker, then myeloperoxidase, CD117, CD99, CD68/PG-M1, lysozyme, CD34, terminal deoxynucleotidyl transferase, CD56, CD61, CD30, glycophorin A, and CD4. Different chromosomal abnormalities including MLL rearrangement, t(8; 21), monosomy 7, trisomy 8, trisomy 11, trisomy 4, inversion (16), monosomy 16,16q deletion, 5q deletion, and 20q deletion were reported. Most of the literature about MS are case reports and small retrospective studies, thus there is limited clinical knowledge of the cases and their presentation and management plans. Here, we provide a review of what has been reported in the literature about MS in the light of our experiences.

AB - Hematological malignancies can manifest as extramedullary soft tissue masses in relatively rare cases. The rarity of it causes a diagnostic and therapeutic challenge. One of the rarest manifestations is myeloid sarcoma (MS). MS develops as part of acute myeloid leukemia, myeloproliferative neoplasm, or myelodysplastic syndrome or at relapse, especially following allogeneic hematopoietic stem cell transplant. The tumor displays high myeloperoxidase expression, hence the color green, and is called chloroma. It most commonly appears in lymph nodes, skin and soft tissues, bone, testes, gastrointestinal tract, and peritoneum. Immunohistochemistry shows CD68-KP1 as the most commonly expressed marker, then myeloperoxidase, CD117, CD99, CD68/PG-M1, lysozyme, CD34, terminal deoxynucleotidyl transferase, CD56, CD61, CD30, glycophorin A, and CD4. Different chromosomal abnormalities including MLL rearrangement, t(8; 21), monosomy 7, trisomy 8, trisomy 11, trisomy 4, inversion (16), monosomy 16,16q deletion, 5q deletion, and 20q deletion were reported. Most of the literature about MS are case reports and small retrospective studies, thus there is limited clinical knowledge of the cases and their presentation and management plans. Here, we provide a review of what has been reported in the literature about MS in the light of our experiences.

KW - Chloroma

KW - Extramedullary soft tissue masses

KW - Myeloid sarcoma

KW - Sarcoma

UR - http://www.scopus.com/inward/record.url?scp=85062667432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062667432&partnerID=8YFLogxK

U2 - 10.1159/000497210

DO - 10.1159/000497210

M3 - Review article

VL - 42

SP - 219

EP - 224

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

SN - 2296-5270

IS - 4

ER -